Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology

@article{Seferovic2019ClinicalPU,
  title={Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology},
  author={Petar M. Seferovic and Piotr Ponikowski and Stefan D. Anker and Johann Bauersachs and Ovidiu Chioncel and John G. F. Cleland and Rudolf A. de Boer and Heinz Drexel and Tuvia Ben Gal and Loreena Hill and Tiny Jaarsma and Ewa Anita Jankowska and Markus S. Anker and Mitja Lainscak and Basil S. Lewis and Theresa A. McDonagh and Marco Metra and Davor Mili{\vc}i{\'c} and Wilfried Mullens and Massimo Francesco Piepoli and Giuseppe M C Rosano and Frank Ruschitzka and Maurizio Volterrani and Adriaan A. Voors and Gerasimos Filippatos and Andrew J. S. Coats},
  journal={European Journal of Heart Failure},
  year={2019},
  volume={21}
}
The European Society of Cardiology (ESC) has published a series of guidelines on heart failure (HF) over the last 25 years, most recently in 2016. Given the amount of new information that has become available since then, the Heart Failure Association (HFA) of the ESC recognized the need to review and summarise recent developments in a consensus document. Here we report from the HFA workshop that was held in January 2019 in Frankfurt, Germany. This expert consensus report is neither a guideline… 

Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

TLDR
The purpose of the present article is to highlight the most relevant novelties of the new guidelines and to comment on those aspects that, from a Spanish perspective, could improve understanding and local application.

Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology

TLDR
Advice is provided of the effect HF drugs on renal function as the emerge of several new classes and the recommendation by the 2021 ESC guidelines of early initiation and titration of quadruple disease‐modifying therapies in HFrEF increases the likelihood of treatment‐induced changes in renal function.

Figures of the Heart Failure Association (HFA): Prof. Dr. Tiny Jaarsma, HFA Board Member (2018–2020), Coordinator Patient Care: Management and Delivery Committee and Co‐Chair HFA Task Force on Palliative Care

  • A. Coats
  • Medicine
    European journal of heart failure
  • 2019
Prof. Dr. Tiny Jaarsma has been around in the Heart Failure Association (HFA) for some time and has been active in several activities in the Association and in the journals of HFA. She currently is a

The summary of the 2019 year in heart failure with reduced ejection fraction

TLDR
The present article summarized the main issues regarding heart failure with reduced ejection fraction together with comment based on the HFA expert consensus.

Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology

TLDR
Nine patient profiles that may be relevant for treatment implementation in HF patients with a reduced ejection fraction are identified, taking into account heart rate, the presence of atrial fibrillation, symptomatic low blood pressure, estimated glomerular filtration rate or hyperkalaemia.

All rise! Orthostatic hypotension in heart failure. Letter regarding the article ‘Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients’

TLDR
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management.

Heart failure with mid‐range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines

TLDR
A multiparametric evaluation may contextualize a patient with HFmrEF in a more defined phenotype with a specific prognosis, and it is reasonable to consider other parameters, such as LVEF changes over time, HF aetiology, co‐morbidities, and other imaging parameters.

A year in heart failure: an update of recent findings

TLDR
Treatment of HF with preserved ejection fraction was a major unmet clinical need until this year, when the results of EMPEROR‐Preserved were issued and dapagliflozin reduced by 21% compared with placebo, the primary outcome of cardiovascular death or HF hospitalization.
...

References

SHOWING 1-10 OF 118 REFERENCES

Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology

TLDR
There is an urgent need to develop evidence‐based treatment algorithms to prolong life when possible and in accordance with patient preferences, increase life quality, and reduce the burden of hospitalization in this vulnerable patient population.

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

TLDR
Recent surveys of Guidelines and Expert Consensus Documents published in peer-reviewed journals between 1985 and 1998 have shown that methodological standards were not complied with in the vast majority of cases.

Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

TLDR
Patients with chronic kidney disease and HF are at increased risk of hyperkalaemia and ∼50% of these patients experience two or more yearly recurrences, so RAASi therapy should be down-titrated or more often discontinued even after a single episode of elevated potassium (K+) level.

The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology

TLDR
The manuscript addresses frequently encountered challenges, such as evaluation of congestion and clinical euvolaemia, assessment of diuretic response/resistance in the treatment of acute heart failure, and an approach towards stepped pharmacologic diUREtic strategies, based upon diuretics response.

Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study

TLDR
Patients with HFrEF who were treated with less than 50% of recommended dose of ACE-inhibitors/ARBs and beta-blockers seemed to have a greater risk of death and/or heart failure hospitalization compared with patients reaching ≥100%.

Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy

TLDR
Combined CMR and 99mTc-DPD are helpful imaging tools for accurate phenotyping of patients amenable to histopathological diagnosis or genetic testing, and should be considered for proper management of this population.

Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials

TLDR
Beta-blockers improve LVEf and prognosis for patients with heart failure in sinus rhythm with a reduced LVEF and similar benefit was observed in the subgroup of patients with LVEFs 40-49%, but did not improve prognosis.
...